Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 15/20 | 0.67 |
| ▸ | BCL2A1 | Q16548 | 15/20 | 0.67 |
| ▸ | BCL2 | P10415 | 3/20 | 0.63 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18151714 | 0.92 | MCL1 (0.79) | MCL1BCL2A1BCL2BCL2L1 | |
| SCHEMBL18152271 | 0.91 | MCL1 (0.82) | MCL1BCL2A1BCL2BCL2L1CYP2C9 | |
| SCHEMBL18151920 | 0.90 | MCL1 (0.81) | MCL1BCL2A1BCL2BCL2L1 | |
| SCHEMBL18152033 | 0.89 | MCL1 (0.69) | MCL1BCL2A1BCL2BCL2L1 | |
| SCHEMBL18152045 | 0.89 | MCL1 (0.81) | MCL1BCL2A1BCL2BCL2L1 | |
| SCHEMBL18151899 | 0.88 | MCL1 (0.81) | MCL1BCL2A1BCL2BCL2L1 | |
| SCHEMBL18151925 | 0.87 | MCL1 (0.72) | MCL1BCL2A1BCL2BCL2L1BCL2L2 | |
| SCHEMBL18151724 | 0.83 | MCL1 (0.66) | MCL1BCL2A1BCL2BCL2L1BCL2L2 | |
| SCHEMBL18152207 | 0.83 | MCL1 (0.83) | MCL1BCL2A1BCL2BCL2L1 | |
| SCHEMBL18151722 | 0.82 | BCL2A1 (0.47) | MCL1BCL2A1BCL2BCL2L1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3285583-B1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3285583-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | The Regents of The University of Michigan (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9884841-B2 | Small molecule inhibitors of Mcl-1 and uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-02-06 | — | — | US | disclosed |
| WO-2016172218-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20160304485-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304485-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | MCL1, BCL2L1, BCL2L11 | MCL1 1/4885BCL2A1 6/4885BCL2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.